Endocrinopathies and cardiopathies in patients with Turner syndrome

DOI

https://dx.doi.org/10.18565/aig.2020.2.14-20

Zaidieva Ya.Z., Balan V.E., Serebrennikova K.G.
1) Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russia; 2) Central Clinical Hospital, Russian Academy of Sciences, Moscow, Russia

Ovarian dysgenesis, stunting, and infertility are common characteristics of Turner syndrome (TS). Endocrinopathies and cardiopathies are less common, but can cause significant complications and are a leading cause of death in patients with TS. The prevalence of endocrine abnormalities, including osteoporosis that occurs in almost 60% of patients, hypothyroidism (3.2%) and glucose metabolism disorders (that occur with a variable frequency) are related to the age group. Therapy with estrogens and growth hormones alone or in combination improves bone density in patients with TS. Autoimmune thyroiditis is associated with the X-isochromic phenotype in women with TS in the first and second decades of life. Type 2 diabetes mellitus developing due to Xp haploid gene deficiency and a latent autoimmune β-cell response occurs with higher frequency in TS patients in different age groups. The prevalence of cardiopathies in TS patients is 23%; the most common cardiovascular malformations are coarctation of the aorta and bicuspid aortic valve. The risks of cardiovascular events require ultrasound monitoring throughout a patient’s entire life, during pregnancy in particular. TS patients need interdisciplinary and long-term care. This paper provides an overview of endocrinopathies and cardiopathies in patients with TS.

Turner syndrome

estrogen deficiency

endocrinopathies

cardiopathies

Full text (in Russian)

Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007; 76: 405–10. PMID: 17708142
Faienza M.F., Ventura A., Colucci S. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol (Lausanne). 2016; 7: 34. doi: 10.3389/fendo.2016.00034
Wilson C.A., Heinrichs C., Larmore K.A., Craen M., Brown-Dawson J., Shaywitz S., Ross J., Klein K.O. Estradiol levels in girls with Turner’s syndrome compared to normal prepubertal girls as determined by an ultrasensitive assay. J Pediatr Endocrinol Metab. 2003; 16: 91–6. http://dx.doi.org/10.1515/jpem.2003.16.1.91
Hagen C.P., Main K.M., Kjaergaard S., Juul A. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Hum Reprod. 2010; 25: 3134–41. doi: 10.1093/humrep/deq291
Sowinska-Przepiera E., Andrysiak-Mamos E., Chełstowski K., Adler G. Association between ER-a polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment—a pilot study. J Bone Miner Metab. 2011; 29: 484–92. doi: 10.1007/s00774-010-0247-3
Vanderschueren D., Venken K., Ophoff J., Bouillon R., Boonen S. Clinical Review: sex steroids and the periosteum-reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006; 91: 378–82. http://dx.doi.org/10.1210/jc.2005-1766
Han T.S., Cadge B., Conway G.S. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner’s syndrome. Clin Endocrinol (Oxf). 2006; 65: 643–7. doi: 10.1111/j.1365-2265.2006.02643.x
Suganuma N., Kawai H., Furuhashi M. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy. Arch Gynecol Obstet. 2004; 269: 192–5. doi: 10.1007/s00404-003-0532-7
Sun L., Peng Y., Sharrow A.C., Iqbal J., Zhang Z., Papachristou D.J., Zaidi S., Zhu L.L. FSH directly regulates bone mass. Cell. 2006; 125: 247–60. doi: 10.1016/j.cell.2006.01.051
Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., Bonewald L.F. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231–4. . doi: 10.1038/nm.2452.
Iqbal J., Sun L., Kumar T.R., Blair H.C., Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A. 2006; 103: 14925–30. doi: 10.1073/pnas.0606805103
Balga R., Wetterwald A., Portenier J., Dolder S., Mueller C., Hofstetter W. Tumor necrosis factoralpha: Alternative role as an inhibitor of osteoclast formation in vitro. Bone. 2006; 39: 325–35. doi: 10.1016/j.bone.2006.02.056
Faienza M.F., Brunetti G., Ventura A., Piacente L., Messina M.F., De Luca F. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner’s Syndrome. Bone. 2015; 81: 228–36. doi: 10.1016/j.bone.2015.07.021
Cannon J.G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine. 2011; 53: 141–7. doi: 10.1016/j.cyto.2010.11.011
Cicognani A., Pirazzoli P., Nicoletti A., Baronio F., Conti V., Bonetti S. The SHOX gene: a new indication for GH treatment. J Endocrinol Invest. 2010; 33: 15–8. PMID: 21057180
Bakalov V.K., Axelrod L., Baron J., Hanton L., Nelson L.M., Reynolds J.C. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2010; 88: 5717–22. doi: 10.1210/jc.2003-030913
Frederiksen A.L., Hansen S., Brixen K., Frost M. Increased cortical area and thickness in the distal radius in subjects with SHOX-gene mutation. Bone. 2014; 69: 23–9. doi: 10.1016/j.bone.2014.09.001
Soucek O., Zapletalova J., Zemkova D., Snajderova M., Novotna D., Hirschfeldova K., Plasilova I., Kolouskova S., Rocek M., Hlavka Z. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013; 98: E1:241–7. doi: 10.1210/jc.2013-1113.
Soucek O., Lebl J., Zapletalova J., Novotna D., Plasilova I., Kolouskova S. Bone geometry and volumetric bone density at the radius in patients with isolated SHOX deficiency. Exp Clin Endocrinol Diabetes. 2013; 121: 109–14. doi: 10.1055/s-0032-1333260.
Chiovato L., Larizza D., Bendinelli G., Tonacchera M., Marinó M., Mammoli C., Lorini R., Severi F., Pinchera A. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner’s syndrome. Eur J Endocrinol. 1996; 134: 568–75. doi: 10.1530/eje.0.1340568
Bianchi I., Lleo A., Gershwin M.E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun. 2012; 38: J187–92. doi: 10.1016/j.jaut.2011.11.012.
Cogni G., Chiovato L. An overview of the pathogenesis of thyroid autoimmunity. Hormones (Athens). 2013; 12(1):19–29. doi: 10.1007/BF03401283
Wikiera B., Barg E., Konieczna A., Głab E., Noczyńska A. The prevalence of thyro-peroxidase antibodies and thyroid function in Turner’s syndrome. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006; 12: 190–4. PMID: 17020654
Lichiardopol C., Mota M., Braicu D., Militaru C., Mixich F. Diabetes mellitus and Turner syndrome. Rom J Intern Med. 2007; 45: 299–304. PMID: 18333365
Bakalov V.K., Cheng C., Zhou J., Bondy C.A. X-Chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab. 2009; 94: 3289–96. doi: 10.1210/jc.2009-0384
Zhao L., Guo M., Matsuoka T.A., Artner I., Jarrett H.W., Friedman D. The Islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem. 2009; 280: 11887–94. doi: 10.1074/jbc.M409475200
Dulac Y., Pienkowski C., Abadir S., Tauber M., Acar P. Cardiovascular abnormalities in Turner’s syndrome: What prevention? Arch Cardiovasc Dis. 2008; 101: 85–90. doi: 10.1016/j.acvd.2008.05.007.
Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998; 101(1): E11. doi: 10.1542/peds.101.1.e11
Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas. 2014; 79: 471–5. doi: 10.1016/j.maturitas.2014.08.011.
Mortensen K.H., Hjerrild B.E., Stochholm K., Andersen N.H., Sørensen K.E., Lundorf E., Hørlyck A., Pedersen E.M. .Dilation of the ascending aorta in Turner syndrome – a prospective cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2011; 13: 24. doi: 10.1186/1532-429X-13-24.
Martin L.J., Ramachandran V., Cripe L.H., Hinton R.B., Andelfinger G., Tabangin M., Shooner K., Keddache M., Benson D.W. Evidence in favor of linkage to human chromosomal regions 18q, 5q and 13q for bicuspid aortic valve and associated cardiovascular malformations. Hum Genet. 2007; 121: 275–84. https://doi.org/10.1007/s00439-006-0316-9
McBride K.L., Riley M.F., Zender G.A., Fitzgerald-Butt S.M., Towbin J.A., Belmont J.W., Cole S.E. NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet. 2008; 17: 2886–93. doi: 10.1093/hmg/ddn187.
O’Brien K.D. Epidemiology and genetics of calcific aortic valve disease. J Invest Med. 2007; 55(6): 284–91. doi: 10.2310/6650.2007.00010.
Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009; 47(6): 828–34. doi: 10.1016/j.yjmcc.2009.08.008.
Foffa I., Ait Alì L., Panesi P., Mariani M., Festa P., Botto N., Vecoli C., Andreassi M.G. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. Bmc Med Genet. 2013; 14: 44. doi: 10.1186/1471-2350-14-44.
Wolff D.J., Van Dyke D.L., Powell C.M. Laboratory guideline for Turner syndrome. Genet Med. 2010; 12: 52–5. doi: 10.1097/GIM.0b013e3181c684b2.
Haber H.P., Ranke M.B. Pelvic ultrasonography in Turner syndrome: standards for uterine and ovarian volume. J Ultrasound Med. 2009; 18: 271–6.doi: 10.7863/jum.1999.18.4.271
Marin A., Weir-McCall J.R., Webb D.J., van Beek E.J.R., Mirsadraee S. Imaging of cardiovascular risk in patients with Turner’s syndrome. Clin Radiol. 2015; 70(8): 803–14. doi: 10.1016/j.crad.2015.03.009.
Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., Kleerekoper M., Luckey M.M., McClung M.R. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010; 16: 1016–19.https://doi.org/10.4158/EP.16.6.1016
Bondy C.A. Care of girls and women with Тurner Syndrome: A Guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007; 92(1): 10–25. doi: 10.1210/jc.2006-1374
Gravholt C.H., Andersen N.H., Conway G.S., Dekkers O.M., Geffner M.E., Woelfle J., Backeljauw P.F. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017; 177(3): G1–70. doi: 10.1530/EJE-17-0430.
Stephure D.K.; The Canadian Growth Hormone Advisory Committee. Impact of Growth Hormone Supplementation on Adult Height in Turner Syndrome: Results of the Canadian Randomized Controlled Trial. J Clin Endocrinol Metab. 2005; 90(6): 3360–6. doi: 10.1210/jc.2004-2187
Baronio F., Mazzanti L., Girtler Y., Lupi F., Longhi S. The influence of GH treatment on glucose homeostasis in girls with turner syndrome: a 7- year study. J Clin Endocrinol Metab. 2017; 102(3): 878–83. doi: 10.1210/jc.2016-3179.
Chamberlain J.J., Rhinehart A.S., Shaefer C.J., Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016; 164(8): 542–52. doi: 10.7326/M15-3016
Gravholt C.H. Turner syndrome and the heart: cardiovascular complications and treatment strategies. Am J Cardiovasc Drugs. 2002; 2(6): 401–13. doi: 10.2165/00129784-200202060-00005
Allybocus Z.A., Wang C., Shi Hr., Wu Qh.Endocrinopathies and cardiopathies in patients with Turner syndrome, Climacteric. 2018; 21(6): 536–41. doi: 10.1080/13697137.2018.1501674.
Madriago E., Nguyen T., McFerson M., Larson E.V., Airhart N., Moller J.H., Silberbach M. Frequency and outcomes of cardiac operations and catheter interventions in turner Syndrome. Am J Cardiol. 2012; 110(4): 580–5. doi: 10.1016/j.amjcard.2012.04.036.

Received 01.10.2019

Accepted 04.10.2019

Yansiyat Z. Zaydieva, MD, Professor, Head of the Department of Gynecological Endocrinology, Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow.
101000, Moscow, ul. Pokrovka, 22A.
Vera E. Balan, MD, professor, head of the outpatient department, Moscow Regional Research Institute of Obstetrics and Gynecology, Russian Federation.
101000, Moscow, st. Pokrovka, 22A.
Klara G. Serebrennikova, MD, professor, supervisor of obstetrics and gynecology of the Central Clinical Hospital of the Russian Academy of Sciences.
Moscow, st. Lithuanian, d.1a.

For citation: Zaidieva Ya.Z., Balan V.E., Serebrennikova K.G.
Endocrinopathies and cardiopathies in patients with Turner syndrome.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2020; 2: 14-20 (In Russian).
https://dx.doi.org/10.18565/aig.2020.2.14-20

Endocrinopathies and cardiopathies in patients with Turner syndrome

Zaidieva Ya.Z., Balan V.E., Serebrennikova K.G.

Keywords

References

About the Authors

Similar Articles